Kim Minsoo, Jung Na Young, Park Chang Kyu, Chang Won Seok, Jung Hyun Ho, Chang Jin Woo
Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.
Stereotact Funct Neurosurg. 2017;95(4):279-286. doi: 10.1159/000478866. Epub 2017 Aug 16.
Treatment options for patients with drug-resistant essential tremor (ET) are limited. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is an emerging technique to treat refractory ET.
To present MRgFUS as an alternative to radiofrequency (RF) thalamotomy or deep brain stimulation (DBS) for ET treatment.
We retrospectively analyzed 59 patients who underwent unilateral surgery for drug-resistant ET. Treatments included RF thalamotomy (n = 17), DBS (n = 19), and MRgFUS (n = 23). The outcomes measured were tremor severity and treatment-related complications.
At 1 month postoperatively, 100% of RF thalamotomy patients, 89.5% of DBS patients, and 91.3% of MRgFUS patients exhibited absent/mild tremor (successful treatment); other patients exhibited partial relief. At 12 months postoperatively, treatment success for each procedure was observed in 70.6, 84.2, and 78.3% of patients, respectively. At 1 month postoperatively, treatment-related complications had occurred in 58.8, 5.3, and 13.0% of patients, respectively. At 12 months postoperatively, side effects persisted in 11.8, 21.1, and 4.4% of patients, respectively. No statistical differences in treatment success were observed between treatments or over time. Complication rates differed between treatment modalities (p < 0.01) and were lowest in the MRgFUS group.
Patients with drug-resistant ET received equivalent results from RF thalamotomy, DBS, and MRgFUS. DBS and MRgFUS resulted in fewer treatment-related complications.
耐药性特发性震颤(ET)患者的治疗选择有限。磁共振引导聚焦超声手术(MRgFUS)是一种治疗难治性ET的新兴技术。
介绍MRgFUS作为射频(RF)丘脑切开术或脑深部电刺激(DBS)治疗ET的替代方法。
我们回顾性分析了59例因耐药性ET接受单侧手术的患者。治疗方法包括RF丘脑切开术(n = 17)、DBS(n = 19)和MRgFUS(n = 23)。测量的结果是震颤严重程度和与治疗相关的并发症。
术后1个月,100%的RF丘脑切开术患者、89.5%的DBS患者和91.3%的MRgFUS患者震颤消失/减轻(治疗成功);其他患者症状部分缓解。术后12个月,各手术方法的治疗成功率分别为70.6%、84.2%和78.3%。术后1个月,分别有58.8%、5.3%和13.0%的患者发生了与治疗相关的并发症。术后12个月,分别有11.8%、21.1%和4.4%的患者仍有副作用。治疗成功率在不同治疗方法之间或随时间变化均未观察到统计学差异。不同治疗方式的并发症发生率有所不同(p < 0.01),且MRgFUS组最低。
耐药性ET患者接受RF丘脑切开术、DBS和MRgFUS的治疗效果相当。DBS和MRgFUS导致的与治疗相关的并发症较少。